申请人:Jubilant Epicore LLC
公开号:US11352322B2
公开(公告)日:2022-06-07
The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.
本公开描述了通式(I)的新型化合物及其类似物、同分异构体、立体异构体、多晶型、水合物、溶液、药学上可接受的盐、药物组合物、代谢物和原药。这些化合物可同时抑制 LSD 和 HDAC,可用作治疗或改善涉及细胞生长的疾病的药物,如恶性肿瘤、精神分裂症、阿尔茨海默病、帕金森病等。